The EPS beat is a function of cost-cutting and share dilution, not revenue growth. With no near-term catalysts until 2H 2026 (ALX2004 safety data) and mid-2027 (ASPEN-09-Breast topline), the stock is likely to trade on pipeline sentiment and cash runway. Monitor for any early data disclosures or partnership announcements.
Price Chart
Executive Summary
ALX Oncology reported Q2 2026 results with a GAAP net loss of ($0.13) per share, beating consensus estimates of ($0.16) by 18.8%. The company highlighted on-track enrollment for its Phase 2 ASPEN-09-Breast trial (data mid-2027) and ALX2004 Phase 1 safety data (2H 2026), along with a strengthened balance sheet via a new $50M debt facility.
Key Financial Metrics
Key Facts
- GAAP net loss of ($0.13) per share for Q2 2026 vs consensus ($0.16) — a 18.8% beat.
- Cash, cash equivalents and investments of $153.4M as of June 30, 2026, sufficient to fund operations through first half of 2028.
- Enrollment on track for Phase 2 ASPEN-09-Breast trial (topline data mid-2027) and Phase 1 ALX2004 trial (safety data 2H 2026).
- Refinanced existing $10M debt with HSBC and secured ability to draw up to an additional $20M through June 2028, lowering cost of capital.
- Appointed Scott Garland as Chairman and Michael Listgarten as General Counsel in June 2026.
Financial Impact
Q2 2026 GAAP net loss of ($18.0M) improved from ($25.9M) in Q2 2025, driven by lower R&D and G&A expenses. Cash burn remains the primary financial metric for this pre-revenue company.
Risk Factors
- Pre-revenue clinical-stage biotech with no approved products; all value depends on clinical trial outcomes.
- Dilution risk remains high given the $150M equity offering in February 2026 and potential future draws on the $50M debt facility.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-336843 |
| Document: alxo-20260806.htm | 0001193125-26-336843 |
| Document: 0001193125-26-336843-index-headers.html | 0001193125-26-336843 |
| Document: 0001193125-26-336843-index.html | 0001193125-26-336843 |
| Document: 0001193125-26-336843.txt | 0001193125-26-336843 |
| 8-K Data (Synthetic) | 0001193125-26-336843 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 10d ago | SC 13D/A | $1.14 $1.13 | ▼ −0.88% | ▼ −0.73% | $1.10 (−3.51%) |
Oct 15, 2026 12d ago | 8-K | $1.06 $1.17 | ▲ +10.38% | ▲ +10.81% | $1.10 (+3.77%) |
Sep 28, 2026 29d ago | Press Release | $1.39 $1.21 | ▼ −12.95% | ▼ −14.15% | $1.10 (−20.86%) |
Aug 15, 2026 10w ago | Institutional Cluster | $1.97 $1.99 | ▲ +1.02% | ▲ +2.21% | $1.10 (−44.16%) |
Aug 6, 2026 11w ago | 8-K | $2.11 $1.94 | ▼ −8.06% | ▼ −9.27% | $1.10 (−47.87%) |
Jun 30, 2026 17w ago | 8-K | $2.06 $2.36 | ▲ +14.56% | ▲ +14.30% | $1.10 (−46.60%) |
Jun 26, 2026 17w ago | 8-K | $2.20 $2.19 | ▼ −0.45% | ▼ −1.84% | $1.10 (−50.00%) |
Jun 12, 2026 19w ago | Institutional Cluster | $1.58 $1.53 | ▲ +3.16% | ▲ +3.84% | $1.10 (+30.38%) |
May 8, 2026 24w ago | 8-K | $2.08 $2.04 | ▼ −1.92% | ▼ −3.39% | $1.10 (−47.12%) |
May 8, 2026 24w ago | Press Release | $2.08 $2.04 | ▲ +1.92% | ▲ +3.39% | $1.10 (+47.12%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers